Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocotrienol prodrug - VGI Health Technology

Drug Profile

Tocotrienol prodrug - VGI Health Technology

Alternative Names: IVB-002; IVB-004

Latest Information Update: 16 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monash Institute of Pharmaceutical Sciences
  • Developer Monash Institute of Pharmaceutical Sciences; VGI Health Technology
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Hepatoprotectants; Small molecules; Tocotrienols
  • Mechanism of Action Antioxidants; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic fatty liver disease; Pancreatic cancer

Most Recent Events

  • 14 Feb 2022 VGI Health Technology executes a non-binding Term Sheet for the sale of Invictus Biopharma Pty Ltd Group (Invictus Group) to Invictus BioPharma Holdings Ltd (IVBHL)
  • 14 Feb 2022 Monash Institute of Pharmaceutical Sciences plans formal preclinical studies in H2 of 2022
  • 30 Jun 2021 VGI Health Technologies plans a clinical trial for Non-alcoholic fatty liver disease (PO) in 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top